| Description | Furnidipine significantly reduced AoD and AF and had antiarrhythmic and cardioprotective effects at low doses in a rat model. |
| In vivo | Pre-treatment period for oral Furnidipine doses (1, 5, or 10 mg/kg) was 1 h, whereas for the intravenous Furnidipine ones (1.25, 2.5, 5, or 10 microg/kg) was 10 min. After both routes of administration, significant protective effects of furnidipine on creatine kinase release were observed after the two lowest doses only. In contrast, its higher dosages were more effective in preventing re-perfusion-induced mortality, arrhythmias and hypotensive episodes, and for transiently lowering arterial blood pressure before initiation of ischemia.[1] |
| molecular weight | 416.42 |
| Molecular formula | C21H24N2O7 |
| CAS | 138661-03-7 |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: < 1 mg/mL (insoluble） |
| References | 1. Krzemiński TF, et al. Anti-arrhythmic and cardio-protective effects of furnidipine in a rat model: a dose response study. Eur J Pharmacol. 2006;549(1-3):91-97. 2. Maroto R, et al. Effects of omega-conotoxin MVIIC on veratridine-induced cytotoxicity and cytosolic Ca(2+) oscillations. Brain Res. 1996;714(1-2):209-214. 3. Krzemiński TF, et al. Differential effects of furnidipine and its active metabolites in rat isolated working heart. Vascul Pharmacol. 2008;49(2-3):91-96. |